scyllo-inositol Terminated Phase 2 Trials for Alzheimer's Disease (AD) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01766336A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease